Big pharma deal incoming.

A deal is on the horizon

On the day the IND was opened Paul Rennie said in an interview that he received a number of phone calls from big pharma to congratulate him on the IND opening and wanting to talk further.

On the Bell Potter Healthcare day.

"As I mentioned at the outset we have been very pleasantly surprised with the number of the inbound inquiries from US, Europe and Asia.....discussions ongoing....this is a very valuable asset......feelers to all of the major players....the asset has a large number of benefits over and above the osteoarthritis pipeline"

This week, Paul Rennie immediately transitions to Chairman appointing an interim CEO so he can focus on Strategic Relationships. Coppo reports further on it, commenting deal focus is now front of mind and it is inevitable that they will do a distribution deal.

PAR releases Clarivate market research that they have conducted globally to assist with negotiations, pricing the drug at around US$2500 per course for OA pain and $6,000 US if it is proven as DMOAD, and will become frontline if it gets the DMOAD label.

Feel free to add any more points/data/evidence to this thread.

Deal incoming.